People usually search for this
BPC-157/TB-500 10+10mg
$160.00
Products will arrive in a lyophilized (powder) form for maximum stability
This co-lyophilized blend combines two of the most extensively studied repair peptides: BPC-157 for VEGFR2-mediated angiogenesis and TB-500 for actin sequestration and cell migration. The complementary mechanisms address sequential phases of tissue healing in preclinical models. Supplied as a 10mg + 10mg blended lyophilized vial at ≥99% HPLC purity per component, for research use only.
Volume discounts
Auto-applied at checkout
Free shipping on orders of $200+
Compound Identity
COMPOUND NAME
BPC-157 and TB-500 peptide blend
SYNONYMS
Body Protection Compound-157 (BPC-157), Thymosin Beta-4 Fragment (TB-500)
CAS NUMBER
BPC-157: 137525-51-0 TB-500: 77591-33-4
MOLECULAR FORMULA
BPC-157: C62H98N16O22 TB-500: C212H350N56O78S
MOLECULAR WEIGHT
BPC-157: 1419.53552 g/mol TB-500: ~4963.49 g/mol
STRUCTURE
Synthetic tetrapeptide
PEPTIDE SEQUENCE
BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val TB-500: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Lys-Asp-Lys-Ser-Ile-Lys-Asn-Asp-Lys-Pro-Thr
CHEMICAL STRUCTURE
BPC-157: TB-500:
CHEMICAL STRUCTURE
- BPC-157: C62H98N16O22
- TB-500: C212H350N56O78S
Mechanism of Action
BPC-157 is believed to act via modulation of nitric oxide pathways, angiogenesis induction, and cytoprotective effects through VEGFR-2 and FAK-paxillin pathways. TB-500 (a synthetic peptide fragment of thymosin beta-4) enhances cellular migration and blood vessel formation primarily through actin regulation and upregulation of angiogenic factors. Together, they may work synergistically to accelerate tissue regeneration and suppress inflammatory responses by targeting overlapping and complementary pathways1-4.
Biological Activity
BPC-157 promotes wound healing, tendon and ligament repair, and has demonstrated gastroprotective and neuroprotective effects in animal models. TB-500 supports cell migration, differentiation, angiogenesis, and anti-inflammatory responses, especially in damaged muscle, myocardium, and epithelium. In combination, the blend is hypothesized to support faster and more comprehensive healing by acting on distinct phases of tissue repair1-4.
Storage
- Store at -20°C, protect from light.
Drug Categories
Research peptides, Regenerative therapeutics (investigational)
Additional Notes
For investigational use in laboratory settings only.
Summary Table
Property
Description
CAS Number
137525-51-0 (BPC-157), 77591-33-4 (TB-500)
Molecular Formula
C62H98N16O22; C212H350N56O78S
Molecular Weight (MW)
1419.54; 4963.49 g/mol
Mechanism of Action
Modulation of angiogenic, cytoprotective, and anti-inflammatory pathways
Biological Activity
Wound healing, anti-inflammatory, myogenesis
Supplied Form
Lyophilized peptide blend
Purity
≥99% (HPLC)
Storage
–20°C, desiccated, protected from light
Drug Categories
Research peptides, Regenerative therapeutics (investigational)
Additional Notes
For research use. Undergoing clinical trials in multiple disease areas
Disclaimer
For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.
Detailed Product Description
The BPC-157 + TB-500 peptide blend combines two investigational agents with complementary regenerative actions. BPC-157, derived from a gastric protein, has been extensively studied for its ability to accelerate wound healing, protect the gastrointestinal lining, and enhance tendon regeneration. TB-500, a synthetic analog of thymosin beta-4, has demonstrated benefits in modulating actin dynamics, improving cell migration, and promoting angiogenesis. Together, the blend is hypothesized to offer enhanced therapeutic value in tissue repair models by acting through converging signaling pathways like FAK, eNOS, and VEGF1-4.
Research Highlights
No peer-reviewed studies published as of June 2025. Information developed based on pharmacology of the individual peptides.
Synergistic Effects of BPC-157 + TB-500
- Convergent Angiogenesis: Both peptides enhance VEGF signaling, with BPC-157 focusing on VEGFR-2-mediated endothelial proliferation and TB-500 supporting vascular matrix remodeling and MMP-driven pathways1-4.
- Complementary Anti-Inflammatory Profiles: Their combined action may reduce systemic inflammation while promoting regenerative cytokines, creating a favorable environment for healing.
- Enhanced Cellular Dynamics: BPC-157 promotes fibroblast alignment and adhesion, while TB-500 supports actin-mediated motility-together improving wound closure and tissue architecture restoration1,4.
- Broadened Tissue Tropism: The blend may extend regenerative action across muscle, tendon, nerve, and epithelial tissues, thereby enhancing functional recovery in diverse models of injury.
Pharmacokinetic Profile
Route of Administration
Subcutaneous
- Route of Administration: Subcutaneous Injection
Formulation & Handling
- Supplied as a lyophilized powder or aqueous solution.
- Store at –20°C in a dry, light-protected environment.
Selected Clinical Trial Activity
BPC-157 + TB-500 is a research-grade compound that has been studied in laboratory settings but has not undergone full clinical development. It is not approved for therapeutic use in humans, and no large-scale clinical trials have been conducted to evaluate its safety or efficacy as a medication. BPC-157 + TB-500 is supplied strictly for laboratory research and investigational purposes only.
References
1
Sikiric, P. et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr. Pharm. Des. 17, 1612–1632 (2011).
2
Sikiric, P. et al. BPC 157 and blood vessels. Curr. Pharm. Des. 25, 1970–1984 (2019).
3
Goldstein, A. L., Hannappel, E. & Kleinman, H. K. Thymosin ?4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol. Med. 18, 442–448 (2012).
4
Malinda, K. M. et al. Thymosin ?4 accelerates wound healing. J. Invest. Dermatol. 113, 364–368 (1999).
Enlarged image of chemical structure. Source: PubChem (BPC-157), PubChem (BPC-157)
Quality & Purity
This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →
Related Products
Bioregulators
Vesugen 20mg
$70.00
Read more 
Exercise
MOTS-C 40mg
$200.00
Add to cart 
GHRP
Tesamorelin 20mg
$200.00
Add to cart You may also like…
BPC-157/TB-500/GHK-Cu 10+10+50mg (GLOW blend 70mg)
Summary Description: The GLOW Peptide Blend is a synthetic combination of three well-characterized regenerative peptides: BPC-157, TB-500, and GHK-Cu, each with complementary mechanisms that promote cellular repair, angiogenesis, and tissue remodeling. The blend integrates the nitric oxide-mediated cytoprotective activity of BPC-157, the actin-regulating and pro-angiogenic functions of TB-500, and the copper-mediated antioxidant and anti-fibrotic properties of GHK-Cu. Collectively, this tri-peptide formulation provides a multifaceted approach to studying regeneration, inflammation resolution, and extracellular matrix restoration in preclinical models
Products will arrive in a lyophilized (powder) form for maximum stability
BPC-157/TB-500/KPV/GHK-Cu 10+10+10+50mg (KLOW blend 80mg)
Summary Description: The KLOW Peptide Blend is a comprehensive anti-aging and regenerative peptide complex that combines BPC-157, TB-500, GHK-Cu, and KPV to restore cellular vitality, improve tissue resilience, and counteract age-related degeneration. This synergistic formulation targets several hallmarks of aging (chronic inflammation, oxidative stress, vascular decline, and collagen loss) to promote youthful structural integrity and enhanced cellular function1-5.
Products will arrive in a lyophilized (powder) form for maximum stability
Related products
BPC-157 10mg
Summary Description: BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of a protein found in human gastric juice. In preclinical models, it has demonstrated pro-angiogenic, cytoprotective, and anti-inflammatory properties1-3. BPC-157 accelerates tissue repair across tendon, ligament, muscle, and epithelial models by modulating nitric oxide pathways, upregulating VEGF and other growth factors, and promoting fibroblast migration4. Its chemical stability in gastric environments and efficacy across multiple administration routes make it a candidate for further investigation in regenerative pharmacology2.
Products will arrive in a lyophilized (powder) form for maximum stability
BPC-157 5mg
Summary Description: BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of a protein found in human gastric juice. In preclinical models, it has demonstrated pro-angiogenic, cytoprotective, and anti-inflammatory properties1-3. BPC-157 accelerates tissue repair across tendon, ligament, muscle, and epithelial models by modulating nitric oxide pathways, upregulating VEGF and other growth factors, and promoting fibroblast migration4. Its chemical stability in gastric environments and efficacy across multiple administration routes make it a candidate for further investigation in regenerative pharmacology2.
Products will arrive in a lyophilized (powder) form for maximum stability
CJC-1295 (No DAC)/Ipamorelin Blend 5+5mg
Summary Description: The CJC-1295 (no DAC) + Ipamorelin peptide blend merges two potent growth hormone secretagogues to synergistically enhance physiologic GH pulsatility. This research-only combination stimulates both GHRH and ghrelin receptor pathways, yielding amplified and sustained GH release while maintaining endocrine feedback sensitivity.
Products will arrive in a lyophilized (powder) form for maximum stability
GLP-1 10mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
Pinealon 20mg
Summary Description: Pinealon is a synthetic tripeptide developed as a neuroprotective and geroprotective agent. It exerts potent antioxidant effects, modulates cellular signaling, and supports cognitive function, cell viability, and adaptation to stress. Pinealon has been extensively studied in animal models for its efficacy in reducing oxidative stress, supporting learning and memory, and modulating key brain neurotransmitter and receptor systems1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
SS-31 50mg
Summary Description: SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that binds selectively to cardiolipin in the inner mitochondrial membrane. It acts as a mitochondrial protective agent, stabilizing mitochondrial structure, enhancing oxidative phosphorylation, reducing production of reactive oxygen species (ROS), and mitigating cellular damage in diverse models of mitochondrial dysfunction. Owing to its unique structure and mode of action, SS-31 demonstrates potential therapeutic value across cardiovascular diseases, neurodegenerative disorders, kidney injury, and myopathies associated with mitochondrial dysfunction1-6.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 20mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability
Tirzepatide 15mg
Summary Description: Tirzepatide is a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. Engineered as a synthetic peptide based on the native GIP sequence and modified for extended half-life via fatty acid conjugation, tirzepatide delivers glycemic control, profound weight loss, and cardiometabolic benefits. Its imbalanced receptor affinity and biased signaling provide enhanced insulin secretion and improved metabolic outcomes beyond selective GLP-1 agonism.1,3,4
Products will arrive in a lyophilized (powder) form for maximum stability